{"id":"https://openalex.org/W4286298682","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps4610","title":"Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy.","display_name":"Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4286298682","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps4610"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.tps4610","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps4610","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps4610","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017490262","display_name":"Amishi Yogesh Shah","orcid":"https://orcid.org/0000-0002-9007-0621","observed_orcids":["https://orcid.org/0000-0002-9007-0621"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amishi Yogesh Shah","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069915515","display_name":"Jianjun Gao","orcid":"https://orcid.org/0000-0001-6138-4472","observed_orcids":["https://orcid.org/0000-0001-6138-4472"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jianjun Gao","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083442694","display_name":"Arash Rezazadeh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arash Rezazadeh","raw_affiliation_strings":["University of California Irvine, Orange, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California Irvine, Orange, CA;","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078663038","display_name":"Suzanne Cole","orcid":"https://orcid.org/0000-0001-8390-6315","observed_orcids":["https://orcid.org/0000-0001-8390-6315"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suzanne Cole","raw_affiliation_strings":["University of Texas Southwestern Medical Center, Dallas, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical Center, Dallas, TX;","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023152191","display_name":"Rohit Jain","orcid":"https://orcid.org/0000-0002-9295-9360","observed_orcids":["https://orcid.org/0000-0002-9295-9360"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rohit K. Jain","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036232556","display_name":"Alex Stevenson","orcid":"https://orcid.org/0000-0002-0537-1017","observed_orcids":["https://orcid.org/0000-0002-0537-1017"]},"institutions":[{"id":"https://openalex.org/I4210127683","display_name":"4D Pharma (United Kingdom)","ror":"https://ror.org/046qhgy77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210127683"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alex Stevenson","raw_affiliation_strings":["4D Pharma Plc, Leeds, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4D Pharma Plc, Leeds, United Kingdom;","institution_ids":["https://openalex.org/I4210127683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073139313","display_name":"Gayle Fyvie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127683","display_name":"4D Pharma (United Kingdom)","ror":"https://ror.org/046qhgy77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210127683"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gayle Fyvie","raw_affiliation_strings":["4D Pharma plc, Leeds, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4D Pharma plc, Leeds, United Kingdom;","institution_ids":["https://openalex.org/I4210127683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000068893","display_name":"Nina Jane Gaw","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127683","display_name":"4D Pharma (United Kingdom)","ror":"https://ror.org/046qhgy77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210127683"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nina Jane Gaw","raw_affiliation_strings":["4D pharma plc, Leeds, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4D pharma plc, Leeds, United Kingdom;","institution_ids":["https://openalex.org/I4210127683"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084349853","display_name":"Shubham Pant","orcid":"https://orcid.org/0000-0001-9281-480X","observed_orcids":["https://orcid.org/0000-0001-9281-480X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shubham Pant","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"TPS4610","last_page":"TPS4610"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12996","display_name":"Bacterial Cancer Therapy","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1305","display_name":"Biotechnology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.8700000047683716},{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.878000020980835},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8140000104904175},{"id":"https://openalex.org/keywords/enterococcus","display_name":"Enterococcus","score":0.6230000257492065},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6150000095367432},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.49000000953674316},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.7900000214576721},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.5740000009536743},{"id":"https://openalex.org/keywords/immune-microenvironment","display_name":"immune microenvironment","score":0.3700000047683716},{"id":"https://openalex.org/keywords/metastatic-bladder-cancer","display_name":"metastatic bladder cancer","score":0.5649999976158142},{"id":"https://openalex.org/keywords/locally-advanced-bladder-cancer","display_name":"locally advanced bladder cancer","score":0.7110000252723694},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.47999998927116394},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9169999957084656},{"id":"https://openalex.org/keywords/objective-response","display_name":"objective response","score":0.8519999980926514}],"concepts":[{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.9359501004219055},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8247586488723755},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.5991079211235046},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5836747884750366},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5350749492645264},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.49158939719200134},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4475661516189575},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4434681534767151},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4172608256340027},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4096660912036896},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.38466697931289673},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3770405650138855},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36903658509254456},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.16830116510391235},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.11356335878372192},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.tps4610","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps4610","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps4610","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4244177126","https://openalex.org/W3137251658","https://openalex.org/W4387595262","https://openalex.org/W4406587256","https://openalex.org/W2586222551","https://openalex.org/W4411715865","https://openalex.org/W4407585419","https://openalex.org/W3101442442","https://openalex.org/W4410816921","https://openalex.org/W3214089132"],"abstract_inverted_index":{"TPS4610":[0],"Background:":[1],"Efficacy":[2],"of":[3,8,25,34,58,68,79,98,204,212,252,294,317,327,341,352,365,380],"avelumab":[4,26,207,261],"for":[5,27,36,105,111],"maintenance":[6,28,210],"treatment":[7,29,110,337,376],"UC":[9,43,215,232],"was":[10,103],"investigated":[11],"in":[12,107,114,117,132,141,161,174,208,267,357],"the":[13,22,31,99,202,209,295,358,383],"JAVELIN":[14],"Bladder":[15],"100":[16],"study":[17,199,221],"(NCT02603432),":[18],"which":[19],"led":[20],"to":[21,151,206,291,307,320,382],"FDA":[23],"approval":[24],"as":[30,137,361],"current":[32],"standard":[33],"care":[35],"patients":[37,225],"with":[38,48,143,226,269],"locally":[39,228],"advanced":[40,229],"or":[41,230,246,285],"metastatic":[42,213,231],"that":[44,102,126,182],"have":[45,124,239],"not":[46],"progressed":[47],"first-line":[49],"platinum-based":[50],"chemotherapy.":[51,255],"Outcomes":[52],"included":[53],"median":[54,64],"overall":[55],"survival":[56,66],"(OS)":[57],"21.4":[59],"months":[60,70],"(95%":[61,71,81],"CI":[62,72,82],"0.56-0.86),":[63],"progression-free":[65],"(PFS)":[67],"3.7":[69],"3.5-5.5)":[73],"and":[74,116,140,154,157,163,167,171,189,297,322,335,360,368,374,385],"objective":[75],"response":[76,245],"rate":[77],"(ORR)":[78],"9.7%":[80],"6.8-13).":[83],"MRx0518":[84,127,147,183,205,277,342],"is":[85,95,196,388],"a":[86,96,197,243],"novel,":[87],"human":[88],"gut":[89],"microbiome-derived,":[90],"single-strain,":[91],"live":[92],"biotherapeutic.":[93],"It":[94],"bacterium":[97],"Enterococcus":[100],"genus":[101],"selected":[104],"development":[106],"solid":[108],"tumor":[109,130,359],"its":[112],"strong":[113],"vitro":[115,162],"vivo":[118,122],"immunostimulatory":[119],"activity.":[120],"In":[121,176],"studies":[123],"shown":[125,150],"can":[128,185],"inhibit":[129],"growth":[131],"different":[133],"syngeneic":[134],"cancer":[135],"models":[136],"both":[138,356],"monotherapy":[139,184],"combination":[142,268],"immune":[144,192],"checkpoint":[145],"inhibitors.":[146],"has":[148],"been":[149],"reduce":[152],"Treg":[153],"increase":[155,164,186],"Th1":[156],"Tc1":[158],"lymphocyte":[159],"differentiation":[160],"intratumoral":[165],"CD4+":[166],"CD8+":[168],"T":[169],"cells":[170,173],"NK":[172],"vivo.":[175],"clinical":[177],"studies,":[178],"preliminary":[179],"data":[180],"shows":[181],"anti-tumor":[187],"TILs":[188],"systemic":[190],"pro-inflammatory":[191],"signaling":[193],"molecules.":[194],"This":[195],"pilot":[198],"evaluating":[200],"whether":[201],"addition":[203],"setting":[211],"platinum-treated":[214],"may":[216],"improve":[217],"outcomes.":[218],"Methods:":[219],"The":[220],"will":[222,257,349,377],"enroll":[223],"30":[224],"unresectable":[227],"at":[233,301,331],"multiple":[234],"US":[235],"centers.":[236],"Patients":[237,256],"must":[238],"measurable":[240],"disease":[241,248,281,323],"after":[242,375],"partial":[244],"stable":[247],"on":[249,299,336],"4-6":[250],"cycles":[251],"platinum-containing":[253],"induction":[254],"receive":[258],"800":[259],"mg":[260],"IV":[262],"infusion":[263],"every":[264],"2":[265],"weeks":[266,340],"1":[270],"oral":[271],"capsule":[272],"(10x1010":[273],"\u2013":[274],"10x1011":[275],"CFU)":[276],"twice":[278],"daily":[279],"until":[280],"progression,":[282],"patient":[283],"withdrawal":[284],"unacceptable":[286],"toxicity.":[287],"Primary":[288],"objectives":[289,305],"are":[290,306],"assess":[292,308],"safety":[293],"combination,":[296],"effect":[298],"PFS":[300],"6":[302],"months.":[303],"Secondary":[304],"other":[309],"efficacy":[310],"measures":[311],"including":[312],"PFS,":[313],"ORR,":[314],"OS,":[315],"duration":[316],"response,":[318,321],"time":[319],"control":[324],"rate.":[325],"Collection":[326],"paired":[328],"research":[329],"biopsies":[330],"baseline":[332],"(after":[333,338],"chemotherapy)":[334],"8":[339],"+":[343],"avelumab),":[344],"plus":[345],"longitudinal":[346],"blood":[347],"sampling,":[348],"allow":[350,378],"investigation":[351,379],"immunological":[353],"changes":[354,381],"systemically":[355],"potential":[362],"predictive":[363],"markers":[364],"response.":[366],"Stool":[367],"urine":[369],"samples":[370],"collected":[371],"before,":[372],"during":[373],"microbiome":[384],"metabolome.":[386],"Recruitment":[387],"open,":[389],"awaiting":[390],"accrual.":[391],"Clinical":[392],"trial":[393],"information:":[394],"NCT05107427.":[395]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-07-21T00:00:00"}